Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:HEB
CUSIPN/A
Phone+1-407-2718516
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-1,391.11%
Return on Equity-49.30%
Return on Assets-32.57%
Miscellaneous
EmployeesN/A
Outstanding Shares47,250,000
Market Cap$14.21 million
Hemispherx BioPharma (NYSEAMERICAN:HEB) Frequently Asked Questions
What is Hemispherx BioPharma's stock symbol?
Hemispherx BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "HEB."
How were Hemispherx BioPharma's earnings last quarter?
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) released its quarterly earnings results on Wednesday, August, 15th. The specialty pharmaceutical company reported ($0.05) EPS for the quarter. The specialty pharmaceutical company had revenue of $0.03 million for the quarter. Hemispherx BioPharma had a negative return on equity of 49.30% and a negative net margin of 1,391.11%. View Hemispherx BioPharma's Earnings History.
When is Hemispherx BioPharma's next earnings date?
Are investors shorting Hemispherx BioPharma?
Hemispherx BioPharma saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 455,743 shares, a decrease of 14.7% from the August 15th total of 534,083 shares. Based on an average trading volume of 229,235 shares, the short-interest ratio is currently 2.0 days. Approximately 1.0% of the company's stock are short sold. View Hemispherx BioPharma's Current Options Chain.
Who are some of Hemispherx BioPharma's key competitors?
Some companies that are related to Hemispherx BioPharma include BELLUS Health (BLU), Medicenna Therapeutics (MDNA), Destiny Pharma (DEST), NovaBay Pharmaceuticals (NBY), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), OptiBiotix Health (OPTI), Scancell (SCLP), Synthetic Biologics (SYN), DiaMedica Therapeutics (DMA), Antibe Therapeutics (ATE), Biopharmx (BPMX), Realm Therapeutics (RLM), Ceapro (CZO) and Nuvo Pharmaceuticals (NRI).
Who are Hemispherx BioPharma's key executives?
Hemispherx BioPharma's management team includes the folowing people:
- Mr. Thomas K. Equels, Exec. Vice Chairman, CEO & Pres (Age 65)
- Mr. Adam Pascale, CFO & Chief Accounting Officer (Age 70)
- Mr. Peter W. Rodino III, J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. (Age 67)
- Mr. Wayne S. Springate, Sr. VP of Operations (Age 47)
- Dr. David R. Strayer, Chief Scientific Officer & Medical Director (Age 72)
Has Hemispherx BioPharma been receiving favorable news coverage?
Media headlines about HEB stock have trended somewhat positive on Friday, according to Accern Sentiment. The research group identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hemispherx BioPharma earned a news impact score of 0.18 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Hemispherx BioPharma.
How do I buy shares of Hemispherx BioPharma?
Shares of HEB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hemispherx BioPharma's stock price today?
One share of HEB stock can currently be purchased for approximately $0.24.
How big of a company is Hemispherx BioPharma?
Hemispherx BioPharma has a market capitalization of $14.21 million.
How can I contact Hemispherx BioPharma?
Hemispherx BioPharma's mailing address is 860 N Orange Ave Ste B, ORLANDO, FL 32801-5205, United States. The specialty pharmaceutical company can be reached via phone at +1-407-2718516.
MarketBeat Community Rating for Hemispherx BioPharma (NYSEAMERICAN HEB)
MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote "Outperform" if you believe HEB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEB will underperform the S&P 500 over the long term. You may vote once every thirty days.
